VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
WGS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
WGSGeneDx Holdings Corp.
$47.29$1.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksWGSFinancials

GeneDx Holdings Corp. (WGS) Income Statement

6Y historyFree accessUpdated daily

Revenue reached $123.1M in Q3 2026 with gross margin of 69.9%, yet operating margin of -8.5% and GAAP net loss of -$12.3M show that operating leverage has not yet turned the business profitable.

Income StatementBalance SheetCash FlowRatios

WGS Income Statement

Annual statement

WGS Income Statement

GeneDx Holdings Corp. (WGS) annual income statement — 6-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20
Sales/Revenue460.78M427.54M305.45M202.57M234.69M212.19M179.32M
Revenue Growth %14.57%39.97%50.79%-13.69%10.6%18.33%-
Cost of Goods Sold149.35M129.37M111.05M112.56M261.44M228.8M175.3M
COGS % of Revenue-30.26%36.36%55.57%111.4%107.82%97.75%
Gross Profit311.43M298.17M194.4M90.01M-26.75M-16.6M4.03M
Gross Margin %67.59%69.74%63.64%44.43%-11.4%-7.82%2.25%
Gross Profit Growth %-53.38%115.98%436.47%-61.13%-512.37%-
Operating Expenses379.22M311.25M217.61M270.6M640.9M429.55M246.02M
OpEx % of Revenue-72.8%71.24%133.59%273.08%202.43%137.19%
Selling, General & Admin304.19M239.22M168.48M194.71M338.24M318.73M163.93M
SG&A % of Revenue-55.95%55.16%96.12%144.12%150.2%91.41%
Research & Development80.86M72.03M45.72M58.27M86.2M105.16M72.7M
R&D % of Revenue-16.85%14.97%28.76%36.73%49.56%40.54%
Other Operating Expenses-1000K03.41M17.63M216.46M5.66M9.39M
Operating Income-67.79M-11.8M-23.21M-180.6M-667.65M-446.15M-241.99M
Operating Margin %-14.71%-2.76%-7.6%-89.15%-284.48%-210.25%-134.95%
Operating Income Growth %-49.16%87.15%72.95%-49.65%-84.36%-
EBITDA-40.49M13.42M-1.26M-146.86M-608.34M-424.34M-230.26M
EBITDA Margin %-8.79%3.14%-0.41%-72.5%-259.21%-199.98%-128.41%
EBITDA Growth %-219.55%1165.24%99.14%75.86%-43.36%-84.29%-
D&A (Non-Cash Add-back)27.3M25.22M21.95M33.73M59.31M21.81M11.73M
EBIT-107.01M-18.6M-49.6M-170.19M-457.51M-242.56M-238.87M
Net Interest Income-4.2M-2.54M-3.03M1.11M-666K-2.76M-1.97M
Interest Income0001.11M2.54M79K506K
Interest Expense4.2M2.54M3.03M03.21M2.83M2.47M
Other Income/Expense-43.42M-9.34M-29.42M3.9M69.62M200.76M654K
Pretax Income-111.21M-21.14M-52.63M-176.69M-598.03M-245.39M-241.34M
Pretax Margin %-24.13%-4.94%-17.23%-87.23%-254.81%-115.64%-134.58%
Income Tax877K-116K-343K-926K-49.05M00
Effective Tax Rate %-0.79%0.55%0.65%0.52%8.2%0%0%
Net Income-111.05M-21.02M-52.29M-175.77M-548.98M-245.39M-241.34M
Net Margin %-24.1%-4.92%-17.12%-86.77%-233.91%-115.64%-134.58%
Net Income Growth %-5431.2%59.8%70.25%67.98%-123.72%-1.68%-
Net Income (Continuing)-112.08M-21.02M-52.29M-175.77M-548.98M-245.39M-241.34M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)-3.72-0.73-1.94-7.23-53.63-74.93-146.94
EPS Growth %-6366.67%62.37%73.17%86.52%28.43%49.01%-
EPS (Basic)--0.73-1.94-7.23-53.63-74.93-33.16
Diluted Shares Outstanding29.88M26.89M26.89M24.31M10.24M3.28M5.63M
Basic Shares Outstanding29.88M26.89M26.89M24.31M10.24M3.28M5.63M
Dividend Payout Ratio-------

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetAdequate
Cash FlowImproving
Top Statement Risk

Persistent GAAP losses and regulatory overhang

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Growth Sustained Across Eight Quarters

According to reported quarterly figures, WGS grew revenue from $70.5M in Q2 2024 to $123.1M in Q3 2026, with year-over-year growth of 5.4% in the latest quarter signaling deceleration from earlier 40-plus percent rates.

The sharp deceleration to 5.4% year-over-year in Q3 2026, after 40-66% comparisons through 2025, suggests the easy base effects that drove the early inflection are fading. Sequential growth from $114.4M to $123.1M is encouraging, but investors should monitor whether exome and genome volume growth can sustain high-single-digit or better rates as comparisons harden. The data does not isolate volume versus pricing contributions, so the durability of ASP gains remains unverified.

Gross Margin Recovery Lacks Pricing Confirmation

Based on reported figures, gross margin expanded from 60.9% in Q2 2024 to roughly 69.9% in Q3 2026, a level that compares favorably with the 64.8% gross margin of peer Natera.

The roughly nine-point gross margin improvement is consistent with a mix shift toward higher-complexity testing and better lab throughput, though the filings supplied do not separate these drivers. Gross margin dipped to 65.2% in Q4 2025 before recovering, indicating the figure is sensitive to quarterly revenue adjustments and COGS timing. Sustaining near-70% margins will depend on whether reimbursement rates hold against payer pressure.

Operating Leverage Emerging but Not Yet Positive

As reported in the income statement, operating loss narrowed from -$17.5M in Q2 2026 to -$10.4M in Q3 2026 as SG&A held near $79M, implying partial operating leverage on a revenue base still below breakeven.

Operating margin improved from -25.6% in Q1 2026 to -8.5% in Q3 2026, suggesting that incremental gross profit is outpacing overhead growth. SG&A remains very high relative to revenue at roughly 64% of sales, so margin expansion depends heavily on continued top-line growth without proportional cost increases. Investors should watch whether SG&A growth stays flat as revenue scales toward the $135M full-year guidance.

Net Income Volatility Obscures Underlying Trend

Based on reported figures, net income swung from a -$63.3M loss in Q1 2026 to a -$12.3M loss in Q3 2026, with EPS volatility reflecting one-time items and a per-share figure that remains unverified in the source data.

The gap between operating loss and net loss in several quarters, including Q1 2026 where net loss was more than double the operating loss, suggests non-operating or discontinued-operations items that warrant further investigation. Stock-based compensation of $8.3M in Q3 2026 is a meaningful share of revenue and inflates the cost base relative to cash operating performance. Adjusted net income guidance of roughly $12M for the full year is non-GAAP, so investors should reconcile it against GAAP results before relying on it.

Guidance Implies Sharp Profitability Step-Up

Based on reported guidance, full-year 2026 adjusted net income of roughly $12M against Q3 GAAP net loss of -$12.3M implies a substantial fourth-quarter swing that warrants skepticism about execution.

The guided profit inflection requires a quarter-over-quarter improvement well beyond the trajectory seen in recent quarters, and the operating margin of -8.5% in Q3 remains negative. Bears would argue that adjusted metrics exclude recurring costs such as stock compensation and restructuring, flattering the apparent progress. Proposed FDA oversight of laboratory developed tests could also raise compliance costs and delay launches, pressuring margins if the regulatory path materializes.

WGS — Frequently Asked Questions

Quick answers to the most common questions about buying WGS stock.

What was GeneDx Holdings Corp.'s (WGS) revenue in 2025?

For fiscal year 2025, GeneDx Holdings Corp. (WGS) reported total revenue of $427.5M. This represents a 138.4% increase compared to $179.3M in 2020.

Is GeneDx Holdings Corp. (WGS) profitable?

GeneDx Holdings Corp. (WGS) reported a net loss of $21.0M for the fiscal year ending 2025.

What is GeneDx Holdings Corp.'s operating profit margin?

GeneDx Holdings Corp. (WGS) reported an operating income of $-11.8M, resulting in an operating profit margin of -2.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is GeneDx Holdings Corp.'s gross profit and gross margin?

GeneDx Holdings Corp. (WGS) generated $298.2M in gross profit for the year, representing a gross profit margin of 69.7%. This demonstrates the company's core pricing power and production efficiency.